Restructuring proteomics through verification. (December 2010)

• Record Type: Journal Article
• Authors: Boja, Emily; Rivers, Robert; Kinsinger, Christopher; Mesri, Mehdi; Hiltke, Tara; Rahbar, Amir; Rodriguez, Henry
• Is Part Of: Biomarkers in medicine. Volume 4:Number 6(2010)
• Page Start: 799
• Page End: 803
• Publication Date: 2010-12
• Subjects: biomarker -- multiple reaction monitoring mass spectrometry -- proteomics -- verification; Biochemical markers -- Periodicals; 610.28
• DOI: 10.2217/bmm.10.92
• Languages: English
• ISSNs: 1752-0363

Abstract

Proteomics technologies have revolutionized cell biology and biochemistry by providing powerful new tools to characterize complex proteomes, multiprotein complexes and post-translational modifications. Although proteomics technologies could address important problems in clinical and translational cancer research, attempts to use proteomics approaches to discover cancer biomarkers in biofluids and tissues have been largely unsuccessful and have given rise to considerable skepticism. The National Cancer Institute has taken a leading role in facilitating the translation of proteomics from research to clinical application, through its Clinical Proteomic Technologies for Cancer. This article highlights the building of a more reliable and efficient protein biomarker development pipeline that incorporates three steps: discovery, verification and qualification. In addition, we discuss the merits of multiple reaction monitoring mass spectrometry, a multiplex targeted proteomics platform, which has emerged as a potentially promising, high-throughput protein biomarker measurements technology for preclinical 'verification'.